Orphi Therapeutics Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 6

Orphi Therapeutics General Information


Developer of a biotech therapy designed to develop pharmacological chaperones (PCs) for the treatment of monogenic diseases. The company's therapy is insisted with MC4R-linked monogenic obesity and Sandhoff/Tay Sachs disease, enabling patients with medical therapy that can treat blood disorders, cerebral amyloid angiopathy or "CAA," which can cause strokes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Primary Office
  • 7276 Golfcrest Drive
  • San Diego, CA 92119
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orphi Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 21-Jan-2019 00000 Completed Product Development
4. Grant 01-Jan-2017 00.000 00000 Completed Product Development
3. Grant 17-Sep-2015 0000 00000 Completed Product Development
2. Early Stage VC 18-May-2015 $650K $650K Completed Product Development
1. Grant 01-Jan-2015 $375K Completed Product Development
To view Orphi Therapeutics’s complete valuation and funding history, request access »

Orphi Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Canavan Foundation Corporation 000 0000 000000 0
National Tay-Sachs & Allied Diseases Association Corporation 000 0000 000000 0
Mercury Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »